Extension of Time to File SOU

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1581

Approved for use through 03/31/2024. OMB 0651-0054

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

SOU Extension Request
(15 U.S.C. Section 1051(d))

To the Commissioner for Trademarks:

MARK: SALIOGASE (see, http://uspto.report/TM/90517616/mark.png)
SERIAL NUMBER: 90517616

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Saliogen Therapeutics, Inc., having an address of
      245 First Street, 18th Floor
      Cambridge, Massachusetts 02142
      United States
      Email: XXXX
Proposed: Saliogen Therapeutics, Inc., having an address of
      245 First Street, 18th Floor
      Cambridge, Massachusetts 02142
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 12/14/2021.

For International Class 001:
Current identification: Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


For International Class 005:
Current identification: Pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological, dyslipidemias musculoskeletal, oncological disorders and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      Rachelle A. Dubow, Esq.
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; michelle.raynes@morganlewis.com; jennifer.kagan@morganlewis.com

Correspondence Information (proposed):
      Rachelle A. Dubow, Esq.
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@morganlewis.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): rachelle.dubow@morganlewis.com; michelle.raynes@morganlewis.com; jennifer.kagan@morganlewis.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $250 will be submitted with the form, representing payment for 2 classes.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Jeff Kopacz/      Date Signed: 06/09/2022
Signatory's Name: Jeff Kopacz, M.S., J.D.
Signatory's Position: Senior Vice President of Intellectual Property & Contracts
Signature method: Sent to third party for signature

PAYMENT: 90517616
PAYMENT DATE: 06/09/2022

Serial Number: 90517616
Internet Transmission Date: Thu Jun 09 14:59:29 ET 2022
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.XX-202206091459298
24467-90517616-800724efa882f52bb7325cee7
814dc02f5e61d4111dd57dc83d962079ad1fa3d-
DA-59261231-20220608092029554428